Teva Pharmaceutical Industries Limited Ordinary Shares
TEVA · NYSE
TEVA · NYSE
Teva is a pharmaceutical company whose portfolio includes generic medicines, branded drugs and biosimilars. Its branded products include Austedo, Ajovy and Uzedy, which the supplied evidence identifies as growth drivers, while the FDA has approved DEGEVMA, a biosimilar to Xgeva. The Motley Fool snippet cites forecasts for Teva's branded portfolio to generate $3.7 billion in revenue next year; the evidence does not give current revenue by segment or a breakdown between branded and generic sales. Teva serves the pharmaceutical and healthcare markets. It reports FY2025 revenue of $17.3 billion and net income of $1.4 billion, versus a net loss of $1.6 billion on $16.5 billion revenue in FY2024.
Teva fell 2.95%, from $40.06 on September 21 to $38.88 on September 28. Shares declined over the first three sessions, closing at $39.01 on Wednesday, then rebounded to $40.22 on Thursday before retreating on Friday and Monday, giving back the full rebound and more. The supplied evidence does not establish a company-specific catalyst during these trading sessions: it includes discussion of branded-drug momentum and FDA approval for the DEGEVMA biosimilar, but provides no publication dates that tie either item to the move. Nor does it provide a market or pharmaceutical-sector benchmark to explain the retreat in broader trading terms.
Teva rose $2.76, or 8.71%, from $31.67 on July 28 to $34.43 on August 4. The decisive move came July 29, when the stock jumped to $34.71 on 17.8 million shares after second-quarter results showed sales above expectations and a higher 2026 revenue outlook, despite an earnings miss. Shares extended gains to $35.41 on July 30, then gave back $0.40 by July 31 and slipped another $0.55 over August 3-4. The reported catalysts were innovative-drug growth and the raised revenue view, while Emalex acquisition costs weighed on profit and lower generic Revlimid sales constrained revenue. The supplied evidence identifies no additional market-wide driver.
